Status:
COMPLETED
Efficacy of Fish Oil in Lupus Patients
Lead Sponsor:
Michelle Petri M.D.,MPH
Conditions:
Systemic Lupus Erythematosus
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The investigators hypothesize that low-dose dietary supplementation with omega-3 fish oil will improve disease activity and endothelial function in Systemic Lupus Erythematosus (SLE) patients.
Detailed Description
Patients with SLE have a fifty-fold increased risk of myocardial infarction. This risk is not totally explained by traditional cardiovascular risk factors. In a previous double-blind study of atorvast...
Eligibility Criteria
Inclusion
- Patients with a clinical diagnosis of SLE are eligible.
- Patients must be 18 years of age or older and able to give informed consent.
Exclusion
- SLE patients who are allergic to fish oil or any omega 3 product.
- Patients who are pregnant or are planning to become pregnant or are nursing.
- Omega-3 use within the previous 6 weeks of enrollment.
- Use of warfarin or heparin.
- Patients who have coronary artery disease.
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2011
Estimated Enrollment :
106 Patients enrolled
Trial Details
Trial ID
NCT00828178
Start Date
February 1 2009
End Date
February 1 2011
Last Update
November 18 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Lupus Center, Johns Hopkins University
Baltimore, Maryland, United States, 21205
2
The Johns Hopkins Lupus Center
Baltimore, Maryland, United States, 21205